News Release

FOR RELEASE JULY 18, 2000 AT 7:30 AM EDT
- ----------------------------------------
                  Contacts:

                  Michael J. Quinn
                  President & CEO
                  Premier Laser Systems, Inc.
                  (949) 859-0656 x215

                  Noam Allon
                  President & CEO
                  MediVision Medical Imaging Ltd.
                  (011)-(972) 54-614-847

PREMIER LASER SYSTEMS AGREES TO SELL MAJORITY STAKE IN OPHTHALMIC IMAGING
SYSTEMS TO MEDIVISION

         Irvine, CA (July 18, 2000)....Premier Laser Systems, Inc. (PLSIQ) today
announced that it has signed an agreement with MediVision Medical Imaging, Ltd.,
an Israeli corporation, regarding a transaction in which MediVision will acquire
Premier's stock in Ophthalmic Imaging Systems (OISI), Premier's intercompany
receivable from OIS, and its inventory of OIS products for $3.2 million in cash
and registered stock of MediVision. Under the terms of the agreement, MediVision
will convert the receivable into OIS stock at a conversion price of $0.55 per
share, with MediVision owning 73% of the common stock of OIS at the conclusion
of the transaction. In addition, MediVision will immediately provide up to
$260,000 in secured financing to OIS. After the closing MediVision will loan to
OIS additional working capital amounts up to $1.5 million.

         Noam Allon, Chief Executive Officer of MediVision commented, "Our
investment in OIS reflects high synergy in technology between the companies as
well as in their marketing territories. It enhances each company's strength,
strategies and needs. We estimate that subject to the completion of such a
transaction, MediVision's scope of activity in the United States will
considerably increase."

         Michael J. Quinn, President and Chief Executive Officer of Premier
said, "We believe the proposed transaction with MediVision provides an excellent
recovery on Premier's investment in OIS for the benefit of Premier's creditors
and other stakeholders. It is an important step in the resolution of Premier's
Chapter 11 case." Mr. Quinn also stated that at this juncture Premier is no
longer pursuing a reorganization of its operations, but is instead pursuing
asset sales of individual product lines or all of its remaining assets, or
merger with another company.

         Premier will receive $2.2 million cash at the closing of the
transaction, and $1 million in registered shares of MediVision stock. The number
of shares of MediVision that will be issued to Premier will be determined at
closing. As part of the parties' agreement, MediVision will repurchase the
shares at the issue price eleven weeks after the closing if the shares have not
been previously sold by Premier. MediVision trades on the Euro.NM stock exchange
in Belgium.



         The transaction is subject to customary closing conditions, and
approval by the bankruptcy court in which Premier's Chapter 11 case is pending.

         Premier Laser Systems, which filed for Chapter 11 Bankruptcy protection
in March 2000, is a manufacturer of proprietary medical laser devices and fiber
optic delivery systems with applications in ophthalmology, dentistry, general
surgery and dermatology.

         OIS is a leading provider of ophthalmic digital imaging systems. OIS
has not filed for bankruptcy protection and continues to operate its business in
the normal course.

         MediVision designs, develops, manufactures and markets digital imaging
devices for ophthalmic applications with an emphasis on diagnostics related to
the retina. Thanks to MediVision's array of systems and their interconnectivity
the company applies the "Complete Ophthalmic Digital Department" concept between
geographically distinct clinics or hospitals and physicians. MediVision markets
its range of digital ophthalmic systems in Europe, the United States and the Far
East.





         The statements in this release that relate to future events or
performance, statements about growth, levels of sales and market size, future
manufacturing capacity and efficiencies, future product shipment rates, future
FDA submittals and future product introductions are forward-looking statements
that involve risks and uncertainties, including risks associated with
uncertainties related to the development of markets for and commercial
acceptance of the company's products and services, the availability of
components, competitors' product introductions and other risks identified in the
company's SEC filings. Actual results may differ from those described in these
forward-looking statements. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date hereof.

                                     # # # #